dddmag.com
Drug Discovery & Development  
 
Journal Editors Question Meridia
Editors of a top medical journal call Meridia "another flawed diet pill" and question whether it should stay on the market as a study shows it raises the risk of heart attack and stroke in people with heart problems. ...continue

Major Leap Forward In TB Diagnostics
Scientists are reporting a major advance in diagnosing tuberculosis: A new test can reveal in less than two hours, with very high accuracy, whether someone has the disease and if it's resistant to the main drug for treating it. ...continue

ND Supreme Court Weighs In On Precription Drug Law
Supporters of a voter initiative that could help bring cheaper prescription drugs to North Dakota are hoping a legal technicality won't keep them from getting the issue placed on the ballot. ...continue

The Active Lives of Fat Cells
Scientists are reporting new evidence that fat tissue is far from being a dormant storage depot for surplus calories, it is an active organ that sends chemical signals to other parts of the body, perhaps increasing the risk of heart attacks, cancer, and other diseases. ...continue

Botox Case Settled for $600M
Allergan Inc., the maker of wrinkle-smoothing Botox, says it will pay $600 million to settle a yearslong federal investigation into its marketing of the top-selling, botulin-based drug. ...continue

More Headlines

Cancer Research Moves Forward
Vital Signs, Spring 2010, Cancer ResearchWhile the last few decades have been witness to progress in cancer research, many challenges remain. This edition of Vital Signs reviews new research and new tools that may change the way cancer is diagnosed and treated. ...continue

Vital Signs: Battling Infectious Diseases
Vital Signs - Winter 2009Discovering effective tests for infectious disease in the US is one thing. Making them work in developing countries is another. Read about the latest developments in infectious disease research in Vital Signs, a digital magazine published by Drug Discovery & Development and Bioscience Technology. ...continue

More Vital Signs

Mammalian Cell Lines
Sigma Life Science, the biological products and research services business of Sigma-Aldrich Corporation, announced the global release of a pioneering range of engineered mammalian cell lines. ...continue

Multipurpose Filters
meissnerMeissner’s Steridyne 50 (PVDF) and Ultradyne 50 (PTFE) are multipurpose 50 mm filters for small volume venting, gas and solvent filtration. The filters are offered with stepped hose barb inlet/outlet connections. ...continue

Flow Filtration System
Spectrum Laboratories, Inc. introduces the KrosFlo Research IIi Tangential Flow Filtration (TFF) System. When used with Spectrum’s hollow fiber filters, this compact, fully integrated system provides faster separation of proteins, cells, viruses, nanoparticles, and other macromolecules. ...continue

Recirculating Chiller
Thermo Fisher Scientific Inc. announced the launch of its NESLAB ThermoFlex series of recirculating chillers. The ThermoFlex 24000 has a cooling capacity of 24,000 watts to meet the needs of customers who require a higher level of cooling performance. ...continue

Thermoreversible Gel
The thermo-reversible mountant CyGEL, from Biostatus Ltd. in the UK, enables high resolution imaging of live 3D tumor spheroids cultured in low-adherence conditions and without fixation or cytospin centrifugation. ...continue

More New Technologies

Two Potential Diagnostic Markers for Ischemic Heart Disease Identified
A new study identified the potential use of two diagnostic markers for ischemic heart disease. ...continue

Sleep Duration is Risk Factor for Cardiovascular Disease
A new study suggests that regularly sleeping for more or less than seven hours per day is associated with an increased risk of cardiovascular disease. ...continue

Stem Cells Mitigate Aftermath of Heart Attacks
Implanting tiny plastic scaffolds seeded with genetically engineered stem cells reduced organ damage and led to better cardiac function after a heart attack, according to a recent animal study. ...continue

More Advances in Cardiovascular Disease Research

White Papers
Application Highlight: Improving Peptide Quantitation And Identification in LC/MS Peptide Map Analysis
The enhanced in-spectrum dynamic range of Xevo G2 QTof mass spectrometer enables the system to analyze a digested protein sample that contains components across a wide dynamic range of concentrations. ...continue

Developing, executing and managing the transformation, analysis and submission of clinical research data with SAS® Drug Development
“The medical product development process is no longer able to keep pace with basic scientific innovation.”  Those are harsh words, especially coming from the U.S. Food and Drug Administration (Challenge and Opportunity on the Critical Path for New Medical Products, FDA, March 2004).  Discovery organizations are identifying a lot of promising compounds, but clinical research processes haven’t kept pace with timely testing of all those potential therapies.  The FDA’s Critical Path Initiative makes it clear—it is time for innovation. ...continue

Rotavirus: Multiple Serotypes and the Argument for Rotavirus Vaccination
National pediatric infectious disease experts address the latest scientific information available on rotavirus. ...continue

More White Papers



Structured Drug Design
cos-1Designing a new drug can be faster and more economical when researchers incorporate computational approaches. Software packages let scientists explore more structural options and even make predictions of the properties of new compounds. ...continue

    Drug Discovery

    Drug Development

    Genomics & Proteomics

    Policy & Projections

    Technology Advances

Closer to Human
ds-1New knockout rat models can be more effective predictors of pharmacokinetics. ...continue

ADRCs for Tissue Reconstruction in Cancer
vital-hiw-2Regenerative medicine is a rapidly emerging field using stem cells to repair or restore function to tissues lost or damaged due to the effects of injury, disease, and aging. ...continue

Fluorescence Imaging of Cranial Vasculature in Live Animals
Radiation therapy is one of the most successful treatments for malignant tumors. In addition to causing tumor death it also weakens and collapses the rapidly forming vasculature around the tumor. ...continue

In Vivo Analysis of Bacterial Targeting in Mouse Cancer Models
uvp-hiwIn vivo CCD-based imaging instruments are ideal for both rapid screening and in-depth in vivo analysis for fluorescent protein expressed in plants and animals. ...continue

Multi-modality Imaging of Tumor Burden and Bone Disease in a Mouse Model
crl-hiwReliable models of bone metastasis are needed to develop new drugs for preventing or treating metastatic bone tumors and the subsequent bone erosion. ...continue

PET/CT Imaging for Studying Tumor Response in Preclinical Animal Models of Cervical Cancer
carestream-hiwPreclinical animal models provide researchers with valuable insight into the efficacy and mechanism of action of a therapy in a living animal rather than in isolated cultured cells. ...continue

More Technology Spotlight

Hosted Regulatory-Compliant eDMS for Small to Mid-Sized Companies
Although the science and intellectual property are the prime drivers of value, the quality of the supporting documentation is an increasingly important consideration. ...continue

With A Little Bit of Knowledge and Some Prediction
hiw-3Accurately predicted retention times are useful for everything from the selection of generic methods and development of screening methods to the identification of metabolites and impurities in drug discovery studies. ...continue

Translational Research Foundation Helps Dana-Farber Cancer Institute Accelerate Discovery
Scientists at the Dana-Farber Cancer Institute—one of the leading cancer research and care centers in the United States—have pioneered a new approach to manage the massive amount of data needed to accelerate medical research. ...continue

More How It Works


 

A Novel Approach to Treating Peripheral Arterial Disease
pervasisIn the United States, over eight million adults over age 50 suffer from peripheral arterial disease (PAD), a serious condition that commonly results from progressive narrowing of arteries in the lower extremities due to atherosclerosis. ...continue

Breaking Down the Barriers
clinipaceA new paradigm shift has the ability to transform outsourced clinical research and give rise to a new kind of contract research organization, the digital CRO. ...continue

Hosted Regulatory-Compliant eDMS for Small to Mid-Sized Companies
Although the science and intellectual property are the prime drivers of value, the quality of the supporting documentation is an increasingly important consideration. ...continue

New Targets, Dual Agonists Increase Possibilities for Treating Diabetes
In recent years, treatment strategies for type 2 diabetes have been focused on the development of novel therapeutic options, especially new drugs targeting the incretin system. ...continue

HDL Mimetic Targets Atherosclerosis
CER-001 is an experimental high-density lipoproteins mimetic being developed by Cerenis Therapeutics. This class of drugs removes cholesterol from the vessel wall to treat high-risk atherosclerosis, including acute coronary syndrome. ...continue

More Recommended Reading

Ambry Adds HiSeq and BeadXpress Instruments
Ambry Genetics, a global leader in genomic services, announced that it has acquired the Illumina HiSeq 2000 Next Generation Sequencing System as well as received the first 510(K) approved Illumina BeadXpress Genotyping System. ...continue

Cetero Expands Derm Testing Services
Cetero Research, an early-stage contract research organization, announced the expansion of multiple clinical dermatology and transdermal delivery system services to four Cetero clinical facilities. ...continue

ClinTec Partners With Elephant Capital
ClinTec International, a global clinical research organisation (CRO) announces a financial and strategic partnership with Elephant Capital Plc., an AIM market listed private equity firm. ...continue

More CRO News

FDA Approves LUMIGAN As First-Line Therapy
Allergan, Inc. announced the United States Food and Drug Administration has approved LUMIGAN 0.01% as a first-line therapy indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. ...continue

Idera Pharma Entitled to $3.8M From Merck KGaA
Idera Pharmaceuticals, Inc. announced that it has achieved a milestone, the initiation of a Phase 1b clinical trial of IMO-2055, under its worldwide licensing and collaboration agreement with Merck KGaA. ...continue

Study Shows Tapentadol Effective for Osteoarthritis
Phase 3 safety and efficacy data comparing tapentadol extended release tablets, an investigational pain medication, to placebo in patients with moderate to severe chronic osteoarthritis knee pain have been recently published. ...continue

More Drug Pipeline




Site Sponsors - Advertise with Us